Zacks Investment Research
13 Mar 2026, 17:06 UTC · 27w ago
Verdict
Headline leans bullish. We score UTHR +1.00 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
United Therapeutics' late-stage TETON-2 study of nebulized Tyvaso met its primary and key secondary endpoints for treating idiopathic pulmonary fibrosis (IPF).
More positive than 99% of claims this week
United Therapeutics reported fourth quarter 2025 annual revenues approaching $3.2 billion, with combined Tyvaso sales growing 16% year-over-year.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 85% of claims this week
The company expects a data readout from the phase III TETON-1 study of nebulized Tyvaso in late Q1 or early Q2 2026.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported better-than-expected earnings, strong commercial growth for Tyvaso, and positive top-line clinical data from the TETON-2 study.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
36m ago
−7.2%
Price is moving against the score
$494.63 vs $532.82 close before publication (Mar 12) · not market-adjusted
UTHR chart →
